Top Markets
#1 Islamic Coin Islamic Coin +151.45%
#2 DOVU DOVU +50.49%
#3 Black Phoenix Black Phoenix +34.88%
#4 Velvet Velvet +32.10%
#5 Akedo Akedo +21.65%
#6 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.03%
#7 DoubleZero DoubleZero +15.69%
#8 Cross Cross +12.56%
#9 HOME HOME +12.51%
#10 Not in Employment, Education, or Training Not in Employment, Education, or Training +12.12%
Coin of the day
Islamic Coin Islamic Coin
Settings
Language
ENGLISH
Currency
USD
Theme
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Rank in Stocks #33960
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Share Price
$17.15
Last synced: 2026-08-03
Market Cap
$6.51M
Change (1 day)
9.80%
Change (1 year)
289.77%
Country
US
Trade Galera Therapeutics, Inc. (GRTX)

Category

Healthcare
Revenue for Galera Therapeutics, Inc. (GRTX)
Revenue in Mar 2026 TTM: 0.00
According to Galera Therapeutics, Inc. latest financial reports the company's current revenue (TTM) is 0.00. In 2023 the company made a revenue of 0.00 equal to the revenue in the year 2022 that was 0.00. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Galera Therapeutics, Inc. from 2017 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) 0.00 0.00%
2024 0.00 0.00%
2023 0.00 0.00%
2022 0.00 0.00%
2021 0.00 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
2017 0.00 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE